References
- Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002;65:2263–72
- Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119–22
- Galasko D. An integrated approach to the management of Alzheimer's disease: assessing cognition, function, and behaviour. Eur J Neurol 1998;5(Suppl 4):S9–S17
- Victoroff J, Mack WJ, Nielson KA. Psychiatric complications of dementia: impact on caregivers. Dement Geriatr Cogn Disord 1998;9:50–5
- Tariot PN, Solomon PR, Morris JC, et al, and the Galantamine USA-10 Study Group. A 5-month, randomized, placebocontrolled trial of galantamine in AD. Neurology 2000;54: 2269–76
- Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000;321: 1–7
- Raskind MA, Peskind ER, Wessel T, Yuan W, and the Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54: 2261–8
- Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–95
- Yamada H, Sugiyama T, Ashida T, et al. Medication management skill and regimen compliance are deteriorated in the elderly even without obvious dementia. Yakugaku Zasshi 2001;121:187–90
- Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95: 68–71
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310
- Razadyne ER [prescribing information]. Titusville, NJ: Ortho- McNeil Neurologics, Inc., 2005
- Reminyl Product Monograph. Toronto: Janssen-Ortho Inc., 2005
- Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20:120–32
- Verhaeghe T, Diels L, de Vries R, de Jong J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. J Chromatogr B 2003;789:337–46
- Liu JP, Chow S-C. Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm 1992;20:101–4
- Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15: 657–80